A New FDA-Approved Antibiotic May Help Women With Recurring UTIs

A New FDA-Approved Antibiotic May Help Women With Recurring UTIs

Fact checked by Nick BlackmerViktoriya Skorikova / Getty ImagesThe Food and Drug Administration (FDA) recently approved a new antibiotic to treat urinary tract infections (UTIs).The drug gepotidacin, which will be sold under the brand name Blujepa, is approved for females age 12 and older with uncomplicated UTIs.Recurrent UTIs are common among women, and the bacteria that cause these infections are becoming increasingly resistant to current anti…

For the first time in nearly three decades, the FDA approved a revolutionary antibiotic, Blujepa, which promises to restore peace of mind to those suffering from uncomplicated urinary infections (ICUs). Developed by GSK, this medication comes just in time for a crucial battle against increasingly resistant bacteria. ICUs, a more serious problem than it seems Urinary infections (ICUs) occur when bacteria, especially E. coli, invade the urinary sy…

Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older - AMR Insights

The FDA has approved Blujepa (gepotidacin) for treating uncomplicated urinary tract infections (uUTIs) in female adults and pediatric patients. The FDA approved Blujepa based on positive results from the pivotal phase III EAGLE-2 and EAGLE-3 trials, which demonstrated non-inferiority to nitrofurantoin. The drug’s safety and tolerability profile was consistent with previous trials, with the most common adverse events being gastrointestinal (GI) r…